Abstract
Background
Alcohol consumption in western pregnant women is not uncommon and could be a risk factor for childhood atopic disease. However, reported alcohol intake may be unreliable, and associations are likely to be confounded.
Objective
We aimed to study the relation between prenatal alcohol exposure and atopic phenotypes in a large population-based birth cohort with the use of a Mendelian randomization approach to minimize bias and confounding.
Methods
In white mothers and children in the Avon Longitudinal Study of Parents and Children (ALSPAC) we first analyzed associations between reported maternal alcohol consumption during pregnancy and atopic outcomes in the offspring measured at 7 years of age (asthma, wheezing, hay fever, eczema, atopy, and total IgE). We then analyzed the relation of maternal alcohol dehydrogenase (ADH)1B genotype (rs1229984) with these outcomes (the A allele is associated with faster metabolism and reduced alcohol consumption and, among drinkers, would be expected to reduce fetal exposure to ethanol).
Results
After controlling for confounders, reported maternal drinking in late pregnancy was negatively associated with childhood asthma and hay fever (adjusted odds ratio [OR] per category increase in intake: 0.91 [95% CI, 0.82-1.01] and 0.87 [95% CI, 0.78-0.98], respectively). However, maternal ADH1B genotype was not associated with asthma comparing carriers of A allele with persons homozygous for G allele (OR, 0.98 [95% CI, 0.66-1.47]) or hay fever (OR, 1.11 [95% CI, 0.71-1.72]), nor with any other atopic outcome.
Conclusion
We have found no evidence to suggest that prenatal alcohol exposure increases the risk of asthma or atopy in childhood.
Key words: Alcohol, ADH1B, Mendelian randomization, prenatal exposure, ALSPAC, pregnancy, birth cohort, asthma, atopy
Abbreviations used: ADH, Alcohol dehydrogenase; ALSPAC, Avon Longitudinal Study of Parents and Children (ALSPAC); GWAS, Genome Wide Association Study; PCA, Principal Components Analysis
Experiments in animals have shown that short-term alcohol exposure inhibits TH1 responses and increases TH2 cytokine responses and IgE,1, 2 although longer-term consumption has been shown to reduce airway hyperresponsiveness and allergic inflammation in an adult mouse model.3 In addition, prenatal exposure can impair fetal lung growth and development,4, 5, 6 through increased oxidative stress.7 In humans, reported alcohol intake is positively associated with total IgE cross-sectionally, although associations with allergen-specific sensitization have been inconsistent.8, 9, 10 Studies from Denmark have found that reported alcohol consumption in pregnancy was positively associated with total IgE in cord blood11 and postnatal atopic dermatitis12, 13 but not with hospitalization for asthma in childhood.14 Given these data, and that the prevalence of low-to-moderate alcohol consumption during pregnancy is high (30%-59%) in the United Kingdom, Denmark, Sweden, Australia, and the United States,15, 16, 17, 18, 19, 20 it would seem important to establish whether prenatal alcohol exposure might be contributing to the high prevalence of childhood atopic disease in the west.21
One difficulty with using reported alcohol intake in pregnancy to measure exposure is that underreporting of consumption is common22 and, as with all observational studies, associations may arise spuriously through bias, or because of unmeasured or residual confounding, a particular problem in nutritional epidemiology.23 Randomized trials of alcohol exposure in pregnancy would be unethical, and we are not aware of any trials of alcohol avoidance in pregnancy which have evaluated childhood atopic outcomes. However, causal inference can be strengthened in observational studies with the use of Mendelian randomization to reduce measurement error and to minimize bias and confounding.24, 25 This approach hinges on the principle that genotype is randomly allocated during meiosis, and consequently associations between genetic variants and disease are not generally susceptible to confounding by lifestyle factors. In addition, variants should not be associated with the disease outcome of interest except through their link to the modifiable risk process of interest. In the case of alcohol, a nonsynonymous variant in the alcohol metabolizing gene, alcohol dehydrogenase (ADH)1B, is thought to accelerate ethanol clearance and to inhibit heavy drinking26 and can be used as a proxy for alcohol consumption. The A allele is associated with faster conversion of alcohol to acetaldehyde, and this leads to reduced alcohol consumption. In European populations, this ADH1B variant is associated with aerodigestive cancers,27 thus providing convincing evidence that alcohol causes these conditions. Furthermore, in the Avon Longitudinal Study of Parents and Children (ALSPAC), a United Kingdom population-based birth cohort, the maternal ADH1B gene variant was strongly associated with alcohol use before and during pregnancy, suggesting that it could be used as a reliable instrument to study the consequences of prenatal (and periconceptional) alcohol exposure.28 Indeed, to study the relation between fetal alcohol exposure and cognitive development, we recently used a Mendelian randomization approach in ALSPAC to determine whether genetic variants in alcohol metabolizing genes were associated with childhood IQ.29
In ALSPAC, we have first analyzed whether reported alcohol intake by mothers in pregnancy is associated with risk of atopic disease in the offspring and then examined the relation between the maternal ADH1B gene variant and these outcomes.
Methods
Subjects
ALSPAC is a population-based birth cohort that recruited 14,541 predominantly white pregnant women resident in the Bristol area of the United Kingdom during 1990 to 1992. There were 14,062 live born children, and 13,988 of these children were alive at 1 year of age and subsequently were followed up. The cohort has been followed since birth with annual questionnaires and, since 7 years of age, with objective measures in annual research clinics. The study protocol has been described previously,30, 31 and further information can be found at http://www.alspac.bris.ac.uk. Ethics approval for all aspects of data collection was obtained from the ALSPAC Ethics and Law Committee (IRB 00003312) and the Local Research Ethics Committees.
Exposures
Mothers were asked 8 weeks into their pregnancy to report their current alcohol consumption (how many measures of beer, wine, spirit, or other alcoholic drinks per day on weekdays and weekends), from which the total units/week were derived and then grouped to avoid categories with small numbers (never, 1-2 units/week, 3-4 units/week, ≥5 units/week). At 18 weeks of gestation mothers were asked to recall their alcohol consumption just before the current pregnancy (derived categories: never, <1 unit/week, 1-6 units/week, ≥7 units/week) and in the first 3 months of pregnancy (never, <1 unit/week, >1 unit/week). (Asking about drinking habits just before pregnancy is likely to capture intake in early gestation, before mothers have realized that they have conceived and had a chance to alter their drinking behavior). At 8 weeks after delivery mothers were asked to report their consumption in the last 2 months of pregnancy (never, <1 unit/week, >1 unit/week). We also defined mothers as “binge” drinkers if they reported drinking at least 4 units on 1 or more days (never, 1-2 days, ≥3 days) in the previous month when asked at 18 weeks of gestation.28
Outcomes
When the children were 7.5 years old, mothers were asked, “Has your child had any of the following in the past 12 months: wheezing, asthma, eczema, hay fever?” Children were defined as having current doctor-diagnosed asthma at 7.5 years (primary outcome of interest) if mothers responded positively to the question, “Has a doctor ever actually said that your study child has asthma?” and positively to 1 or both of the questions on wheezing and asthma in the past 12 months.
Atopy at 7 years was defined as a positive reaction (any detectable weal) to Dermatophagoides pteronyssinus, cat, or grass (after subtracting positive saline reactions from histamine and allergen wheals, and excluding children unreactive to 1% histamine). (Atopy defined in this way identified 96% of children sensitized to 26 other allergens in this cohort.32) Serum total IgE (in kU/L) was measured by fluoroimmunoassay with the Pharmacia UNICAP system (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden).
Confounders
In multivariate analyses we controlled for the following potential confounders: maternal factors during pregnancy (smoking, infections, anxiety score, antibiotic use, and paracetamol use); other maternal factors (educational level; housing tenure; financial difficulties; body mass index; age; parity; history of asthma, eczema, rhinoconjunctivitis, migraine); sex of child, season of birth, multiple pregnancy, gestational age, birth weight, head circumference, birth length; postnatal factors (breast-feeding, day care, pets, damp/mold, environmental tobacco smoke exposure, antibiotic and paracetamol use in infancy, number of younger siblings, body mass index at age 7).
Genotyping
The majority of maternal DNA samples were extracted from whole blood and white cells taken during pregnancy, and a minority were buccal DNA extracted from mouthwash samples. A single nucleotide polymorphism (rs1229984 in ADH1B) was typed by KBiosciences Ltd (Hoddesdon, Herts, United Kingdom; www.kbioscience.co.uk) with a competitive allele-specific PCR system (KASPar). The genotype distribution was compatible with no departure from Hardy-Weinberg equilibrium, and the genotyping success rate was >93.3% and error rate <0.25%.28
Statistical analyses
Although the ALSPAC population is largely white, we adopted 2 strategies to reduce the possibility of confounding by population substructure, because the rs1229984 variant is highly ethnically stratified. First, mother-child pairs were excluded from all analyses if the mother’s reported ethnicity was non-white or unknown. Second, to address possible residual confounding by population substructure, we controlled for 10 variables derived by principal components analysis (PCA) from ALSPAC genome-wide association study (GWAS) data.
We used logistic regression to analyze relations of maternal ADH1B genotype with binary outcomes and linear regression to analyze associations with log-transformed total IgE. Analyses of reported alcohol intake in pregnancy were performed before and after controlling for confounders; tests for trend were performed by analyzing reported alcohol exposure associations as linear per category effects. In view of the rarity of the homozygous mutant genotype (A:A), persons with this genotype were grouped together with heterozygotes (G:A), and we assumed a dominant effect for analysis. Previous analyses of this single nucleotide polymorphism in ALSPAC mothers in relation to alcohol intake suggested that this was appropriate.28 We also performed a priori stratified analyses to explore potential interactions between maternal ADH1B genotype and reported alcohol intake in pregnancy. All analyses were performed with Stata version 10.1 (Stata Corporation, College Station, Tex).
Results
Table I shows the association between reported alcohol intake in the last 2 months of pregnancy and other maternal characteristics among mothers for whom data were complete for at least 1 childhood atopic outcome. Mothers who reported drinking alcohol were more likely than mothers who reported never drinking to be older, better educated, financially better off, and to have taken paracetamol in pregnancy. In contrast, Table II shows that the distribution of maternal ADH1B genotype broadly does not vary according to maternal or offspring characteristics.
Table I.
Alcohol consumption (units/wk) |
|||
---|---|---|---|
Never, no. (%) (N = 3780) | <1, no. (%) (N = 2947) | ≥1, no. (%) (N = 1475) | |
Mother’s age | |||
<20 y | 108 (3) | 40 (1) | 9 (1) |
20-24 y | 684 (18) | 338 (11) | 81 (5) |
25-29 y | 1564 (41) | 1258 (43) | 466 (32) |
30-34 y | 1077 (28) | 983 (33) | 630 (43) |
≥35 y | 347 (9) | 328 (11) | 289 (20) |
Parity | |||
0 | 1727 (46) | 1284 (44) | 619 (42) |
1 | 1255 (33) | 1095 (37) | 527 (36) |
≥2 | 716 (19) | 510 (17) | 299 (20) |
Unknown | 82 (2) | 58 (2) | 30 (2) |
Maternal body mass index (kg/m2) | |||
<18.5 | 171 (5) | 109 (4) | 54 (4) |
18.5-24.99 | 2527 (67) | 2108 (72) | 1083 (73) |
25-29.99 | 549 (15) | 403 (14) | 188 (13) |
≥30 | 217 (6) | 116 (4) | 53 (4) |
Unknown | 316 (8) | 211 (7) | 97 (7) |
Mother’s education level | |||
<Ordinary level | 1098 (29) | 558 (19) | 225 (15) |
Ordinary level | 1468 (39) | 1089 (37) | 387 (26) |
≥Advanced level | 1198 (32) | 1292 (44) | 861 (58) |
Unknown | 16 (<1) | 8 (<1) | 2 (<1) |
Housing tenure | |||
Owned/mortgaged | 2915 (77) | 2477 (84) | 1261 (85) |
Rented (public housing) | 436 (12) | 194 (7) | 64 (4) |
Rented (nonpublic housing) | 257 (7) | 152 (5) | 99 (7) |
Unknown/other | 172 (5) | 124 (4) | 51 (3) |
Financial difficulties | |||
None | 1425 (38) | 1111 (38) | 657 (45) |
Some | 1337 (35) | 1144 (39) | 499 (34) |
Many | 904 (24) | 627 (21) | 279 (19) |
Unknown | 114 (3) | 65 (2) | 40 (3) |
Maternal asthma | 246 (7) | 175 (6) | 81 (5) |
Maternal eczema | 422 (11) | 358 (12) | 179 (12) |
Maternal rhinoconjunctivitis | 665 (18) | 585 (20) | 292 (20) |
Maternal migraine | 577 (15) | 398 (14) | 188 (13) |
Maternal anxiety score in pregnancy | |||
0-4 | 1920 (51) | 1514 (51) | 757 (51) |
5-9 | 1218 (32) | 951 (32) | 468 (32) |
≥10 | 335 (9) | 269 (9) | 145 (10) |
Unknown | 307 (8) | 213 (7) | 105 (7) |
Prenatal tobacco exposure (maximum in pregnancy) | |||
Not exposed | 1659 (44) | 1436 (49) | 695 (47) |
Passive only | 1267 (34) | 967 (33) | 472 (32) |
Mother 1-9/d | 283 (7) | 225 (8) | 145 (10) |
Mother 10-19/d | 395 (10) | 211 (7) | 101 (7) |
Mother ≥20/d | 158 (4) | 97 (3) | 54 (4) |
Unknown | 18 (<1) | 11 (<1) | 8 (1) |
Maternal paracetamol use in early pregnancy | |||
Nonuser | 1873 (50) | 1260 (43) | 600 (41) |
User | 1850 (49) | 1654 (56) | 857 (58) |
Unknown | 57 (2) | 33 (1) | 18 (1) |
Maternal paracetamol use in late pregnancy | |||
Nonuser | 2219 (59) | 1580 (54) | 774 (52) |
User | 1447 (38) | 1296 (44) | 662 (45) |
Unknown | 114 (3) | 71 (2) | 39 (3) |
Antibiotic use in late pregnancy | 203 (5) | 209 (7) | 93 (6) |
Maternal cold/flu in pregnancy | 1478 (39) | 1230 (42) | 659 (45) |
Maternal urinary infection in pregnancy | 198 (5) | 157 (5) | 79 (5) |
Maternal other infections in pregnancy | 185 (5) | 191 (6) | 97 (7) |
Includes all women with complete data for at least 1 childhood outcome (wheeze, eczema, hay fever, asthma, atopy, IgE) and self-reported alcohol consumption in the last 2 months of pregnancy.
Table II.
ADH1B genotype |
||
---|---|---|
GG, no. (%) (N = 5033) | AA/GA, no. (%) (N = 268) | |
Mother’s age | ||
<20 y | 86 (2) | 3 (1) |
20-24 y | 671 (13) | 37 (14) |
25-29 y | 2056 (41) | 105 (39) |
30-34 y | 1657 (33) | 93 (35) |
≥35 y | 563 (11) | 30 (11) |
Parity | ||
0 | 2275 (45) | 118 (44) |
1 | 1750 (35) | 92 (34) |
≥2 | 909 (18) | 52 (19) |
Unknown | 99 (2) | 6 (2) |
Maternal body mass index (kg/m2) | ||
<18.5 | 208 (4) | 14 (5) |
18.5-24.99 | 3460 (69) | 192 (72) |
25-29.99 | 726 (14) | 35 (13) |
≥30 | 248 (5) | 9 (3) |
Unknown | 391 (8) | 18 (7) |
Mother’s education level | ||
<Ordinary level | 1186 (24) | 47 (18) |
Ordinary level | 1811 (36) | 108 (40) |
≥Advanced level | 2023 (40) | 113 (42) |
Unknown | 13 (<1) | 0 (0) |
Housing tenure | ||
Owned/mortgaged | 4093 (81) | 222 (83) |
Rented (public housing) | 439 (9) | 23 (9) |
Rented (nonpublic housing) | 297 (6) | 16 (6) |
Unknown/other | 204 (4) | 7 (3) |
Financial difficulties | ||
None | 1957 (39) | 104 (39) |
Some | 1816 (36) | 93 (35) |
Many | 1127 (22) | 66 (25) |
Unknown | 133 (3) | 5 (2) |
Maternal asthma | 314 (6) | 16 (6) |
Maternal eczema | 588 (12) | 32 (12) |
Maternal rhinoconjunctivitis | 970 (19) | 60 (22) |
Maternal migraine | 729 (14) | 38 (14) |
Maternal anxiety score in pregnancy | ||
0-4 | 2664 (53) | 133 (50) |
5-9 | 1594 (32) | 94 (35) |
≥10 | 462 (9) | 32 (12) |
Unknown | 313 (6) | 9 (3) |
Prenatal tobacco exposure (maximum in pregnancy) | ||
Not exposed | 2285 (45) | 133 (50) |
Passive only | 1700 (34) | 94 (35) |
Mother 1-9/d | 405 (8) | 13 (5) |
Mother 10-19/d | 429 (9) | 19 (7) |
Mother ≥20/d | 191 (4) | 9 (3) |
Unknown | 23 (<1) | 0 (0) |
Maternal paracetamol use in early pregnancy | ||
Non user | 2267 (45) | 132 (49) |
User | 2691 (53) | 133 (50) |
Unknown | 75 (1) | 3 (1) |
Maternal paracetamol use in late pregnancy | ||
Non user | 2785 (55) | 158 (59) |
User | 2113 (42) | 104 (39) |
Unknown | 135 (3) | 6 (2) |
Antibiotic use in late pregnancy | 315 (6) | 17 (6) |
Maternal cold/flu in pregnancy | 2060 (41) | 105 (39) |
Maternal urinary infection in pregnancy | 274 (5) | 10 (4) |
Maternal other infections in pregnancy | 292 (6) | 12 (4) |
Includes all women with complete data for at least 1 childhood outcome and ADH1B genotype.
Table E1 (in the Online Repository at www.jacionline.org) shows the association between maternal ADH1B genotype and reported maternal alcohol intake before and during pregnancy. As expected, carriers of the A allele reported a lower intake than those homozygous for the G allele both before and during pregnancy, they were less likely to report binge drinking, and they were more likely to report abstaining from alcohol during pregnancy.
Table III shows the association between self-reported alcohol consumption before and during pregnancy and childhood asthma in persons with complete outcome data. Univariately, evidence was weak for a lower prevalence of asthma in children of mothers who reported consuming alcohol in the last 2 months of pregnancy. After controlling for confounders, evidence was still weak for a lower prevalence of asthma in mothers who reported consuming alcohol in the first 3 months (test for trend, P = .047) and last 2 months of pregnancy (test for trend, P = .074). Table IV shows that, after controlling for confounders, reported maternal alcohol intake in late pregnancy was negatively associated with hay fever in the offspring (test for trend, P = .024). Table E2, Table E3, Table E4, Table E5 (in the Online Repository at www.jacionline.org) show the associations between reported alcohol consumption before and during pregnancy and childhood wheezing, eczema, atopy, and IgE. After controlling for confounders, maternal intake was not associated with any outcome.
Table III.
Univariate analysis, OR (95% CI) | Multivariate analysis, OR (95% CI) | |
---|---|---|
Mother's alcohol intake before pregnancy (units/wk) | ||
Never (n = 446) | 1.0 | 1.0 |
<1 (n = 2860) | 0.88 (0.66-1.18) | 0.93 (0.69-1.26) |
1-6 (n = 3410) | 0.85 (0.64-1.14) | 0.92 (0.68-1.25) |
≥7 (n = 890) | 0.81 (0.57-1.14) | 0.84 (0.59-1.21) |
Test for trend (N = 7606) | 0.95 (0.86-1.04)∗ | 0.96 (0.87-1.05)∗ |
P value | .229 | .383 |
Mother’s current alcohol intake at 8 wk of pregnancy (units/wk) | ||
Never (n = 4728) | 1.0 | 1.0 |
1-2 (n = 973) | 0.97 (0.78-1.20) | 0.96 (0.77-1.20) |
3-4 (n = 524) | 1.06 (0.81-1.39) | 1.03 (0.78-1.37) |
≥5 (n = 659) | 1.02 (0.79-1.30) | 0.93 (0.71-1.20) |
Test for trend (N = 6884) | 1.00 (0.94-1.09)∗ | 0.98 (0.91-1.06)∗ |
P value | .808 | .667 |
Mother’s alcohol intake in first 3 mo of pregnancy (units/wk) | ||
Never (n = 3356) | 1.0 | 1.0 |
<1 (n = 3088) | 0.96 (0.82-1.11) | 0.91 (0.78-1.06) |
≥1 (n = 1148) | 0.89 (0.72-1.09) | 0.81 (0.65-1.00) |
Test for trend (N = 7592) | 0.95 (0.86-1.04)∗ | 0.90 (0.81-0.99)∗ |
P value | .262 | .047 |
Mother’s alcohol intake during last 2 mo of pregnancy (units/wk) | ||
Never (n = 3410) | 1.0 | 1.0 |
<1 (n = 2668) | 0.92 (0.79-1.08) | 0.92 (0.78-1.08) |
≥1 (n = 1327) | 0.83 (0.68-1.02) | 0.83 (0.67-1.02) |
Test for trend (N = 7405) | 0.91 (0.83-1.00)∗ | 0.91 (0.82-1.01)∗ |
P value | .062 | .074 |
Mother’s binge drinking (days in previous month at 18 wk of pregnancy) | ||
Never (n = 6358) | 1.0 | 1.0 |
1-2 (n = 630) | 1.11 (0.87-1.42) | 0.95 (0.74-1.23) |
≥3 (n = 516) | 0.98 (0.75-1.30) | 0.84 (0.63-1.12) |
Test for trend (N = 7504) | 1.02 (0.90-1.15)∗ | 0.92 (0.81-1.05)∗ |
P value | .783 | .235 |
OR, Odds ratio.
OR per category increase in exposure. Multivariate analysis of maternal alcohol intake adjusts for all confounders listed in Methods section.
Table IV.
Univariate analysis, OR (95% CI) | Multivariate analysis. OR (95% CI) | |
---|---|---|
Mother's alcohol intake before pregnancy (units/wk) | ||
Never (n = 449) | 1.0 | 1.0 |
<1 (n = 2875) | 1.28 (0.87-1.87) | 1.27 (0.86-1.89) |
1-6 (n = 3428) | 1.26 (0.87-1.84) | 1.17 (0.79-1.73) |
≥7 (n = 903) | 1.15 (0.74-1.77) | 1.03 (0.66-1.62) |
Test of trend (N = 7655) | 1.0 (0.90-1.11)∗ | 0.96 (0.86-1.07)∗ |
P value | .944 | .437 |
Mother’s current alcohol intake at 8 wk of pregnancy (units/wk) | ||
Never (n = 4753) | 1.0 | 1.0 |
1-2 (n = 977) | 1.02 (0.81-1.30) | 0.95 (0.74-1.22) |
3-4 (n = 530) | 1.02 (0.74-1.39) | 1.04 (0.75-1.44) |
≥5 (n = 670) | 0.70 (0.51-0.97) | 0.71 (0.50-0.99) |
Test for trend (N = 6930) | 0.93 (0.85-1.01)∗ | 0.93 (0.84-1.02)∗ |
P value | .095 | .109 |
Mother’s alcohol intake in first 3 mo of pregnancy (units/wk) | ||
Never (n = 3370) | 1.0 | 1.0 |
<1 (n = 3100) | 0.83 (0.70-0.99) | 0.84 (0.70-1.01) |
≥1 (n = 1172) | 0.88 (0.70-1.11) | 0.91 (0.71-1.17) |
Test for trend (N = 7642) | 0.91 (0.81-1.02)∗ | 0.93 (0.82-1.04)∗ |
P value | .103 | .203 |
Mother’s alcohol intake during last 2 mo of pregnancy (units/wk) | ||
Never (n = 3434) | 1.0 | 1.0 |
<1 (n = 2678) | 0.92 (0.77-1.09) | 0.85 (0.71-1.03) |
≥1 (n = 1346) | 0.83 (0.66-1.05) | 0.77 (0.60-0.99) |
Test for trend (N = 7458) | 0.91 (0.82-1.02)∗ | 0.87 (0.78-0.98)∗ |
P value | .101 | .024 |
Mother’s binge drinking (days in previous month at 18 wk of pregnancy) | ||
None (n = 6396) | 1.0 | 1.0 |
1-2 (n = 633) | 0.91 (0.68-1.23) | 0.96 (0.71-1.31) |
≥3 (n = 523) | 0.73 (0.51-1.04) | 0.78 (0.54-1.13) |
Test for trend (N = 7552) | 0.87 (0.74-1.02)∗ | 0.90 (0.77-1.06)∗ |
P value | .079 | .219 |
OR, Odds ratio.
OR per category increase in exposure. Multivariate analysis of maternal alcohol intake adjusts for all confounders listed in Methods section.
Table V shows the associations between maternal ADH1B genotype and childhood atopic outcomes. Univariately, no association was observed with any outcome. Similarly, among persons with available PCA variables derived from GWAS data, maternal genotype was not associated with any outcome, either univariately or after controlling for all potential confounders, including the 10 PCA variables.
Table V.
Outcome by ADH1B genotype | No. | Univariate maternal effect estimate∗ (95% CI) | No. of reduced data set† | Univariate maternal effect estimate∗ (95% CI) | Multivariate maternal effect estimate∗ (95% CI) |
---|---|---|---|---|---|
Asthma | |||||
G:G | 4524 | 1.0 | 3266 | 1.0 | 1.0 |
A:A/G:A | 231 | 0.98 (0.66-1.47) | 171 | 0.86 (0.53-1.41) | 0.90 (0.54-1.51) |
Total | 4755 | 3437 | |||
P value | .937 | .571 | .699 | ||
Wheezing | |||||
G:G | 4575 | 1.0 | 3280 | 1.0 | 1.0 |
A:A/G:A | 237 | 1.12 (0.75-1.67) | 171 | 1.04 (0.64-1.68) | 1.08 (0.65-1.79) |
Total | 4812 | 3451 | |||
P value | .582 | .867 | .754 | ||
Eczema | |||||
G:G | 4567 | 1.0 | 3295 | 1.0 | 1.0 |
A:A/G:A | 234 | 1.01 (0.71-1.43) | 170 | 1.07 (0.72-1.60) | 1.14 (0.75-1.73) |
Total | 4801 | 3465 | |||
P value | .961 | .730 | .539 | ||
Hay fever | |||||
G:G | 4556 | 1.0 | 3248 | 1.0 | 1.0 |
A:A/G:A | 236 | 1.11 (0.71-1.72) | 171 | 1.12 (0.67-1.87) | 1.15 (0.67-1.97) |
Total | 4792 | 3419 | |||
P value | .653 | .673 | .616 | ||
Atopy | |||||
G:G | 3571 | 1.0 | 2811 | 1.0 | 1.0 |
A:A/G:A | 193 | 1.09 (0.77-1.55) | 152 | 1.12 (0.76-1.65) | 1.23 (0.82-1.84) |
Total | 3764 | 2963 | |||
P value | .610 | .571 | .327 | ||
IgE | |||||
G:G | 2852 | 1.0 | 2404 | 1.0 | 1.0 |
A:A/G:A | 158 | 1.07 (0.82-1.40) | 133 | 0.97 (0.72-1.30) | 0.96 (0.72-1.30) |
Total | 3010 | 2537 | |||
P value | .606 | .815 | .806 |
OR, Odds ratio.
OR (geometric mean ratio for IgE analysis).
Data set reduced because of incomplete PCA variables derived from GWAS data.
No evidence suggests that reported maternal alcohol intake in late pregnancy (comparing 1 or more units per week with never) modified the associations between maternal ADH1B genotype and childhood asthma and other atopic outcomes (Table VI), and no interactions were found with reported alcohol intake during early pregnancy (data not shown).
Table VI.
Outcome by ADH1B genotype | Mother’s alcohol intake (units/wk) never |
Mother’s alcohol intake (units/wk) ≥1 |
||
---|---|---|---|---|
No. | Adjusted estimate∗ (95% CI) | No. | Adjusted estimate∗ (95% CI) | |
Asthma† | ||||
G:G | 2001 | 1.0 | 2372 | 1.0 |
G:A/A:A | 121 | 0.94 (0.53-1.68) | 103 | 1.14 (0.62-2.10) |
Total | 4597 | |||
Wheezing‡ | ||||
G:G | 2024 | 1.0 | 2400 | 1.0 |
G:A/A:A | 124 | 1.26 (0.72-2.19) | 105 | 0.87 (0.43-1.73) |
Total | 4653 | |||
Eczema§ | ||||
G:G | 2018 | 1.0 | 2397 | 1.0 |
G:A/A:A | 121 | 0.89 (0.52-1.52) | 105 | 1.23 (0.75-2.02) |
Total | 4641 | |||
Hay fever‖ | ||||
G:G | 2017 | 1.0 | 2388 | 1.0 |
G:A/A:A | 124 | 0.98 (0.52-1.87) | 104 | 1.23 (0.62-2.46) |
Total | 4633 | |||
Atopy¶ | ||||
G:G | 1538 | 1.0 | 1894 | 1.0 |
G:A/A:A | 102 | 1.29 (0.80-2.09) | 83 | 1.12 (0.65-1.95) |
Total | 3617 | |||
IgE∗∗ | ||||
G:G | 1191 | 1.0 | 1557 | 1.0 |
G:A/A:A | 85 | 1.23 (0.85-1.78) | 70 | 0.91 (0.61-1.36) |
Total | 2903 |
GMR, Geometric mean ratio.
Estimates (OR [GMR for IgE analysis]) are adjusted for all confounders listed in Methods section.
P for interaction = .664.
P for interaction = .411.
P for interaction = .384.
P for interaction = .636.
P for interaction = .710.
P for interaction = .288.
Discussion
In this population-based birth cohort we have shown, using a Mendelian randomization approach, that a maternal ADH1B gene variant (rs1229984), as a proxy for prenatal alcohol exposure, was unrelated to childhood atopic outcomes, suggesting that alcohol consumption during pregnancy is unlikely to be an important cause of these disorders. This conclusion is further reinforced by the lack of evidence for an interaction between maternal ADH1B and reported intake of alcohol in pregnancy; such an interaction, with a weaker or absent effect of the gene in mothers reporting no alcohol intake, would have been expected if there was a causal effect of prenatal alcohol exposure.33 The lack of evidence of association between maternal ADH1B genotype and atopic outcomes in the offspring also suggests that maternal consumption of alcohol before, or periconception, is unlikely to influence childhood asthma and allergies; in ALSPAC the same nonsynonymous variant of ADH1B is strongly associated with alcohol use just before, as well as during, pregnancy.28
Given the principles underpinning Mendelian randomization,34, 35 our genetic findings are much less likely to be confounded by lifestyle or environmental factors than the weak negative associations we observed between reported maternal alcohol intake in late pregnancy and risk of asthma and hay fever in the offspring. Mothers who drank alcohol in pregnancy tended to be older, better educated, and financially better off than mothers who abstained. Although we controlled for a large number of socioeconomic and other background characteristics in the analyses of reported maternal drinking, the possibility of residual or uncontrolled confounding remains. Furthermore, the negative associations between reported maternal intake and childhood asthma and hay fever conflict with the few previous epidemiologic studies that have suggested a positive relation between prenatal alcohol exposure and atopic outcomes.11, 12, 13 Although there is some evidence for a protective effect of alcohol on allergic airway inflammation and airway hyperresponsiveness in an adult mouse model of allergic asthma,3 the mechanisms underlying such an effect and the relevance of these observations to the inception of asthma after prenatal exposure in humans are unclear. In addition, other animal data indicate detrimental effects of prenatal exposure on fetal lung growth and development.4, 5, 6 The findings for hay fever, if real, would be expected to be mediated through an effect on atopy, yet we did not find similar negative associations between reported intake and atopy or IgE. We therefore think it is unlikely that prenatal alcohol exposure in pregnancy protects against asthma and other atopic disease.
In ALSPAC, mothers carrying the minor A allele consumed less alcohol during pregnancy. Previous in vitro data suggested that carriers of this allele metabolize alcohol up to 100 times faster than persons homozygous for the G allele36 and consequently consume less alcohol to avoid the negative effects of high acetaldehyde concentrations; this in turn would reduce exposure of the fetus to alcohol, which readily crosses the placenta. Although a more recent study has suggested that this variant makes a minor contribution to the variation in alcohol metabolism in vivo,37 lack of power because of the variant’s low frequency in European populations is the most likely explanation for this. The utility of ADH1B genotype as a Mendelian randomization instrument has been clearly demonstrated in relation to alcohol-induced cancer.27, 33
Strengths and limitations
Our study has a number of strengths, including ALSPAC’s population-based prospective design and rich data on maternal reported alcohol use in pregnancy, potential confounders and detailed phenotypic outcome measurements. In addition, few other birth cohorts have maternal DNA available. Measurement of maternal ADH1B genotype enabled us to use a Mendelian randomization approach to investigate the relation between prenatal alcohol exposure and atopic outcomes. In contrast, most previous epidemiologic studies of the effects of maternal alcohol use in pregnancy on offspring health have relied on reported consumption, an approach which is highly susceptible to bias and confounding. Although there was potential for associations with ADH1B genotype to be confounded by population substructure, we reduced this possibility by excluding those with reported non-white ethnicity and by performing sensitivity analyses in which we controlled for PCA variables derived from GWAS data. We acknowledge, however, that, given the low minor allele frequency for rs1229984, we lacked power to detect small or modest effects of this variant, as indicated by the confidence intervals around the effect estimates, and also power to detect interactions with reported alcohol intake. We also accept that we have not taken into account the ability of the fetus to metabolize alcohol and hence the potential effect of gene variants in the child on atopic outcomes. Nevertheless, we would argue that the maternal ADH1B gene is likely to have a greater influence on fetal alcohol exposure because it is so strongly associated with maternal drinking behavior. As with any longitudinal study, data were not complete on exposures, outcomes, and confounders for the whole cohort. Therefore, we cannot rule out the possibility that exclusion of children without complete information might have biased our findings for reported alcohol intake; however, importantly, it is unlikely that missing genotype data would bias the main genetic results.
Public health implications
In conclusion, with the use of a Mendelian randomization approach, we have not found evidence to suggest that alcohol consumption in pregnancy increases the risk of childhood atopic disease. Nor did associations with reported intake suggest increased risks. Nevertheless, because of other potential risks to the developing fetus of low-level alcohol consumption, pregnant women should still heed current advice to abstain from consuming alcohol.38, 39
Clinical implications.
Although pregnant women should be advised to abstain from alcohol, this study has reassuringly found no evidence that alcohol exposure in utero increases the risk of atopic disease in the offspring.
Acknowledgments
We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.
Footnotes
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Supported by the UK Medical Research Council, Wellcome Trust grant 092731, and the University of Bristol who provided core support for ALSPAC. L.Z. was funded by a Medical Research Council Population Health Scientist fellowship (grant G0902144). L.Z. and G.D.S. work in a center that receives funding from the MRC (grant G0600705).
Disclosure of potential conflict of interest: A. J. Henderson has been supported by one or more grants from the UK Medical Research Council and the Wellcome Trust. S. M. Ring has been supported by one or more grants from the UK Medical Research Council (grant 74882) and the Wellcome Trust (grant 076467). L. Zuccolo has been supported by one or more grants from the UK Medical Research Council. The rest of the authors declare that they have no relevant conflicts of interest.
Appendix
Table E1.
ADH1B genotype |
||
---|---|---|
GG, No. (%) (N = 5033) | GA/AA, No. (%) (N = 268) | |
Mother’s alcohol intake before pregnancy (units/wk) | ||
Never | 275 (5) | 18 (7) |
<1 | 1820 (36) | 126 (47) |
1-6 | 2273 (45) | 102 (38) |
≥7 | 599 (12) | 20 (7) |
Unknown | 66 (1) | 2 (1) |
Mother’s current alcohol intake at 8 wk of pregnancy (units/wk) | ||
Never | 3074 (61) | 197 (74) |
1-2 | 686 (14) | 30 (11) |
3-4 | 342 (7) | 17 (6) |
≥5 | 454 (9) | 9 (3) |
Unknown | 477 (9) | 15 (6) |
Mother’s alcohol intake in first 3 mo of pregnancy (units/wk) | ||
Never | 2130 (42) | 138 (51) |
<1 | 2035 (40) | 99 (37) |
≥1 | 795 (16) | 27 (10) |
Unknown | 73 (1) | 4 (1) |
Mother’s alcohol intake during last 2 mo of pregnancy (units/wk) | ||
Never | 2211 (44) | 143 (53) |
<1 | 1722 (34) | 81 (30) |
≥1 | 898 (18) | 34 (13) |
Unknown | 202 (4) | 10 (4) |
Mother’s binge drinking (days in previous month at 18 wk of pregnancy) | ||
None | 4164 (83) | 237 (88) |
1-2 | 441 (9) | 14 (5) |
≥3 | 351 (7) | 13 (5) |
Unknown | 77 (2) | 4 (1) |
Includes all women with complete data for at least 1 childhood outcome and ADH1B genotype.
Table E2.
Univariate analysis, OR (95% CI) | Multivariate analysis, OR (95% CI) | |
---|---|---|
Mother’s alcohol intake before pregnancy (units/wk) | ||
Never (n = 452) | 1.0 | 1.0 |
<1 (n = 2888) | 0.91 (0.66-1.24) | 0.96 (0.69-1.32) |
1-6 (n = 3443) | 0.88 (0.65-1.20) | 0.92 (0.67-1.28) |
≥7 (n = 904) | 0.96 (0.67-1.37) | 0.95 (0.65-1.38) |
Test for trend (N = 7687) | 0.99 (0.90-1.09) | 0.98 (0.89-1.08) |
P value | .820 | .703 |
Mother’s current alcohol intake at 8 wk of pregnancy (units/wk) | ||
Never (n = 4779) | 1.0 | 1.0 |
1-2 (n = 981) | 1.08 (0.87-1.34) | 1.03 (0.82-1.30) |
3-4 (n = 530) | 1.12 (0.85-1.49) | 1.08 (0.80-1.44) |
≥5 (n = 671) | 1.05 (0.81-1.37) | 0.95 (0.73-1.25) |
Test for trend (N = 6961) | 1.03 (0.96-1.11)∗ | 0.99 (0.92-1.08)∗ |
P value | .439 | .957 |
Mother’s alcohol intake in first 3 mo of pregnancy (units/wk) | ||
Never (n = 3386) | 1.0 | 1.0 |
<1 (n = 3113) | 1.04 (0.89-1.22) | 0.98 (0.83-1.16) |
≥1 (n = 1174) | 1.05 (0.85-1.30) | 0.95 (0.76-1.19) |
Test for trend (N = 7673) | 1.03 (0.93-1.14)∗ | 0.98 (0.88-1.09)∗ |
P value | .575 | .664 |
Mother’s alcohol intake during last 2 mo of pregnancy (units/wk) | ||
Never (n = 3445) | 1.0 | 1.0 |
<1 (n = 2696) | 0.94 (0.80-1.11) | 0.91 (0.76-1.08) |
≥1 (n = 1346) | 0.98 (0.80-1.20) | 0.92 (0.74-1.14) |
Test for trend (N = 7487) | 0.98 (0.89-1.08)∗ | 0.95 (0.85-1.06)∗ |
P value | .706 | .335 |
Mother’s binge drinking (days in previous month at 18 wk of pregnancy) | ||
None (n = 6423) | 1.0 | 1.0 |
1-2 (n = 637) | 0.97 (0.74-1.27) | 0.85 (0.64-1.13) |
≥3 (n = 523) | 1.12 (0.85-1.49) | 0.99 (0.74-1.33) |
Test for trend (N = 7583) | 1.04 (0.92-1.18)∗ | 0.97 (0.84-1.11)∗ |
P value | .536 | .619 |
OR, Odds ratio.
OR per category increase in exposure. Multivariate analysis of maternal alcohol intake adjusts for all confounders listed in Methods section.
Table E3.
Univariate analysis, OR (95% CI) | Multivariate analysis, OR (95% CI) | |
---|---|---|
Mother’s alcohol intake before pregnancy (units/wk) | ||
Never (n = 451) | 1.0 | 1.0 |
<1 (n = 2880) | 1.08 (0.82-1.43) | 1.03 (0.77-1.36) |
1-6 (n = 3438) | 1.11 (0.85-1.46) | 1.03 (0.78-1.37) |
≥7 (n = 904) | 1.13 (0.83-1.54) | 0.99 (0.72-1.38) |
Test for trend (N = 7673) | 1.03 (0.95-1.12) | 0.99 (0.92-1.09) |
P value | .438 | .970 |
Mother’s current alcohol intake at 8 wk of pregnancy (units/wk) | ||
Never (n = 4766) | 1.0 | 1.0 |
1-2 (n = 980) | 1.07 (0.89-1.29) | 1.04 (0.86-1.26) |
3-4 (n = 530) | 1.00 (0.79-1.28) | 1.02 (0.79-1.32) |
≥5 (n = 670) | 1.13 (0.91-1.40) | 1.12 (0.90-1.40) |
Test for trend (N = 6946) | 1.03 (0.97-1.10)∗ | 1.03 (0.97-1.10)∗ |
P value | .303 | .343 |
Mother’s alcohol intake in first 3 mo of pregnancy (units/wk) | ||
Never (n = 3379) | 1.0 | 1.0 |
<1 (n = 3107) | 0.99 (0.87-1.13) | 0.98 (0.86-1.13) |
≥1 (n = 1174) | 1.06 (0.89-1.26) | 1.08 (0.90-1.31) |
Test for trend (N = 7660) | 1.02 (0.94-1.11)∗ | 1.03 (0.94-1.12)∗ |
P value | .649 | .554 |
Mother’s alcohol intake during last 2 mo of pregnancy (units/wk) | ||
Never (n = 3436) | 1.0 | 1.0 |
<1 (n = 2692) | 1.03 (0.90-1.18) | 0.98 (0.85-1.13) |
≥1 (n = 1346) | 1.18 (0.99-1.39) | 1.11 (0.93-1.33) |
Test for trend (N = 7474) | 1.08 (0.99-1.17)∗ | 1.04 (0.95-1.14)∗ |
P value | .077 | .356 |
Mother’s binge drinking (days in previous month at 18 wk of pregnancy) | ||
None (n = 6411) | 1.0 | 1.0 |
1-2 (n = 637) | 0.84 (0.66-1.05) | 0.84 (0.66-1.07) |
≥3 (n = 522) | 0.92 (0.72-1.18) | 0.93 (0.72-1.20) |
Test for trend (N = 7570) | 0.93 (0.83-1.04)∗ | 0.94 (0.83-1.06)∗ |
P value | .227 | .297 |
OR, Odds ratio.
OR per category increase in exposure. Multivariate analysis of maternal alcohol intake adjusts for all confounders listed in Methods section.
Table E4.
Univariate analysis, OR (95% CI) | Multivariate analysis, OR (95% CI) | |
---|---|---|
Mothers alcohol intake before pregnancy (units/wk) | ||
Never (n = 330) | 1.0 | 1.0 |
<1 (n = 2287) | 1.12 (0.83-1.51) | 1.09 (0.80-1.48) |
1-6 (n = 2717) | 1.21 (0.90-1.62) | 1.08 (0.80-1.47) |
≥7 (n = 725) | 1.40 (1.01-1.94) | 1.22 (0.87-1.73) |
Test of trend (N = 6059) | 1.11 (1.02-1.20)∗ | 1.05 (0.96-1.14)∗ |
P value | .014 | .304 |
Mother’s current alcohol intake at 8 wk of pregnancy (units/wk) | ||
Never (n = 3713) | 1.0 | 1.0 |
1-2 (n = 780) | 1.07 (0.89-1.29) | 1.05 (0.86-1.27) |
3-4 (n = 427) | 0.99 (0.78-1.27) | 1.01 (0.78-1.30) |
≥5 (n = 525) | 0.80 (0.63-1.01) | 0.80 (0.63-1.03) |
Test for trend (N = 5445) | 0.95 (0.89-1.02)∗ | 0.95 (0.89-1.02)∗ |
P value | .167 | .198 |
Mother’s alcohol intake in first 3 mo of pregnancy (units/wk) | ||
Never (n = 2614) | 1.0 | 1.0 |
<1 (n = 2502) | 0.98 (0.86-1.12) | 1.00 (0.87-1.15) |
≥1 (n = 939) | 0.96 (0.80-1.15) | 0.96 (0.79-1.17) |
Test for trend (N = 6055) | 0.98 (0.90-1.07)∗ | 0.99 (0.90-1.08)∗ |
P value | .639 | .776 |
Mother’s alcohol intake during last 2 mo of pregnancy (units/wk) | ||
Never (n = 2615) | 1.0 | 1.0 |
<1 (n = 2133) | 1.04 (0.90-1.19) | 1.01 (0.87-1.16) |
≥1 (n = 1098) | 0.99 (0.83-1.18) | 0.92 (0.76-1.10) |
Test for trend (N = 5846) | 1.0 (0.92-1.09)∗ | 0.96 (0.88-1.05)∗ |
P value | .965 | .429 |
Mother’s binge drinking (days in previous month at 18 wk of pregnancy) | ||
None (n = 5021) | 1.0 | 1.0 |
1-2 (n = 527) | 0.96 (0.77-1.20) | 0.99 (0.78-1.24) |
≥3 (n = 419) | 0.80 (0.61-1.03) | 0.86 (0.66-1.13) |
Test for trend (N = 5967) | 0.91 (0.81-1.02)∗ | 0.94 (0.83-1.06)∗ |
P value | .101 | .319 |
OR, Odds ratio.
OR per category increase in exposure. Multivariate analysis of maternal alcohol intake adjusts for all confounders listed in Methods section.
Table E5.
Univariate analysis, GMR (95% CI) | Multivariate analysis, GMR (95% CI) | |
---|---|---|
Mother’s alcohol intake before pregnancy (units/wk) | ||
Never (n = 254) | 1.0 | 1.0 |
<1 (n = 1816) | 1.07 (0.86-1.34) | 1.11 (0.89-1.38) |
1-6 (n = 2179) | 1.09 (0.88-1.35) | 1.16 (0.93-1.44) |
≥7 (n = 554) | 0.96 (0.75-1.23) | 1.04 (0.81-1.34) |
Test for trend (N = 4803) | 0.98 (0.92-1.05) | 1.01 (0.95-1.08) |
P value | .602 | .715 |
Mother’s current alcohol intake at 8 wk of pregnancy (units/wk) | ||
Never (n = 2920) | 1.0 | 1.0 |
1-2 (n = 649) | 1.0 (0.87-1.16) | 1.01 (0.87-1.16) |
3-4 (n = 345) | 1.10 (0.91-1.32) | 1.08 (0.90-1.30) |
≥5 (n = 436) | 1.08 (0.91-1.27) | 1.06 (0.89-1.25) |
Test for trend (N = 4350) | 1.03 (0.98-1.08)∗ | 1.02 (0.97-1.08)∗ |
P value | .268 | .390 |
Mother’s alcohol intake in first 3 mo of pregnancy (units/wk) | ||
Never (n = 2066) | 1.0 | 1.0 |
<1 (n = 2002) | 1.10 (0.99-1.22) | 1.06 (0.96-1.18) |
≥1 (n = 731) | 1.09 (0.95-1.26) | 1.06 (0.92-1.22) |
Test for trend (N = 4799) | 1.06 (0.99-1.13)∗ | 1.04 (0.97-1.11)∗ |
P value | .095 | .306 |
Mother’s alcohol intake during last 2 mo of pregnancy (units/wk) | ||
Never (n = 2033) | 1.0 | 1.0 |
<1 (n = 1730) | 1.00 (0.90-1.12) | 0.98 (0.88-1.10) |
≥1 (n = 897) | 1.08 (0.95-1.23) | 1.05 (0.92-1.20) |
Test for trend (N = 4660) | 1.04 (0.97-1.10)∗ | 1.02 (0.95-1.09)∗ |
P value | .283 | .584 |
Mother’s binge drinking (days in previous month at 18 wk of pregnancy) | ||
None (n = 3980) | 1.0 | 1.0 |
1-2 (n = 426) | 0.97 (0.82-1.15) | 0.93 (0.79-1.10) |
≥3 (n = 323) | 0.93 (0.77-1.12) | 0.89 (0.73-1.07) |
Test for trend (N = 4729) | 0.96 (0.89-1.05)∗ | 0.94 (0.86-1.02)∗ |
P value | .403 | .158 |
GMR, Geometric mean ratio.
GMR per category increase in exposure. Multivariate analysis of maternal alcohol intake adjusts for all confounders listed in Methods section.
References
- 1.Starkenburg S., Munroe M.E., Waltenbaugh C. Early alteration in leukocyte populations and Th1/Th2 function in ethanol-consuming mice. Alcohol Clin Exp Res. 2001;25:1221–1230. [PubMed] [Google Scholar]
- 2.Waltenbaugh C., Vasquez K., Peterson J.D. Alcohol consumption alters antigen-specific Th1 responses: mechanisms of deficit and repair. Alcohol Clin Exp Res. 1998;22:220S–223S. doi: 10.1097/00000374-199805001-00003. [DOI] [PubMed] [Google Scholar]
- 3.Oldenburg P.J., Poole J.A., Sisson J.H. Alcohol reduces airway hyperresponsiveness (AHR) and allergic airway inflammation in mice. Am J Physiol Lung Cell Mol Physiol. 2012;302:L308–L315. doi: 10.1152/ajplung.00077.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Inselman L.S., Fisher S.E., Spencer H., Atkinson M. Effect of intrauterine ethanol exposure on fetal lung growth. Pediatric Res. 1985;19:12–14. doi: 10.1203/00006450-198501000-00004. [DOI] [PubMed] [Google Scholar]
- 5.Wang X., Gomutputra P., Wolgemuth D.J., Baxi L. Effects of acute alcohol intoxication in the second trimester of pregnancy on development of the murine fetal lung. Am J Obstet Gynecol. 2007;197:269. doi: 10.1016/j.ajog.2007.06.031. [DOI] [PubMed] [Google Scholar]
- 6.Sozo F., O’Day L., Maritz G., Kenna K., Stacy V., Brew N. Repeated ethanol exposure during late gestation alters the maturation and innate immune status of the ovine fetal lung. Am J Physiol Lung Cell Mol Physiol. 2009;296:L510–L518. doi: 10.1152/ajplung.90532.2008. [DOI] [PubMed] [Google Scholar]
- 7.Giliberti D., Mohan S.S., Brown L.A., Gauthier T.W. Perinatal exposure to alcohol: implications for lung development and disease. Paediatr Respir Rev. 2013;14:17–21. doi: 10.1016/j.prrv.2012.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Linneberg A., Nielsen N.H., Madsen F., Frolund L., Dirksen A., Jorgensen T. Factors related to allergic sensitization to aeroallergens in a cross-sectional study in adults: the Copenhagen Allergy Study. Clin Exp Allergy. 2001;31:1409–1417. doi: 10.1046/j.1365-2222.2001.01178.x. [DOI] [PubMed] [Google Scholar]
- 9.Linneberg A., Petersen J., Nielsen N.H., Madsen F., Frolund L., Dirksen A. The relationship of alcohol consumption to total immunoglobulin E and the development of immunoglobulin E sensitization: the Copenhagen Allergy Study. Clin Exp Allergy. 2003;33:192–198. doi: 10.1046/j.1365-2222.2003.01515.x. [DOI] [PubMed] [Google Scholar]
- 10.Gonzalez-Quintela A., Gude F., Boquete O., Rey J., Meijide L.M., Suarez F. Association of alcohol consumption with total serum immunoglobulin E levels and allergic sensitization in an adult population-based survey. Clin Exp Allergy. 2003;33:199–205. doi: 10.1046/j.1365-2222.2003.01582.x. [DOI] [PubMed] [Google Scholar]
- 11.Bjerke T., Hedegaard M., Henriksen T.B., Nielsen B.W., Schiotz P.O. Several genetic and environmental factors influence cord blood IgE concentration. Pediatr Allergy Immunol. 1994;5:88–94. doi: 10.1111/j.1399-3038.1994.tb00223.x. [DOI] [PubMed] [Google Scholar]
- 12.Linneberg A., Petersen J., Gronbaek M., Benn C.S. Alcohol during pregnancy and atopic dermatitis in the offspring. Clin Exp Allergy. 2004;34:1678–1683. doi: 10.1111/j.1365-2222.2004.02101.x. [DOI] [PubMed] [Google Scholar]
- 13.Bisgaard H., Halkjaer L.B., Hinge R., Giwercman C., Palmer C., Silveira L. Risk analysis of early childhood eczema. J Allergy Clin Immunol. 2009;123:1355–1360. doi: 10.1016/j.jaci.2009.03.046. [DOI] [PubMed] [Google Scholar]
- 14.Yuan W., Sorensen H.T., Basso O., Olsen J. Prenatal maternal alcohol consumption and hospitalization with asthma in childhood: a population-based follow-up study. Alcohol Clin Exp Res. 2004;28:765–768. doi: 10.1097/01.alc.0000125348.23133.88. [DOI] [PubMed] [Google Scholar]
- 15.Kelly Y.J., Sacker A., Gray R., Kelly J., Wolke D., Head J. Light drinking during pregnancy: still no increased risk for socioemotional difficulties or cognitive deficits at 5 years of age? J Epidemiol Community Health. 2012;66:41–48. doi: 10.1136/jech.2009.103002. [DOI] [PubMed] [Google Scholar]
- 16.Statistics on Alcohol:England, 2007. Health and Social Care Information Centre. Available from: http://www.hscic.gov.uk/pubs/alcohol07. Accessed May 20, 2013.
- 17.Andersen A.M.N., Andersen P.K., Olsen J., Gronbaek M., Strandberg-Larsen K. Moderate alcohol intake during pregnancy and risk of fetal death. Int J Epidemiol. 2012;41:405–413. doi: 10.1093/ije/dyr189. [DOI] [PubMed] [Google Scholar]
- 18.Goransson M., Magnusson A., Bergman H., Rydberg U., Heilig M. Fetus at risk: prevalence of alcohol consumption during pregnancy estimated with a simple screening method in Swedish antenatal clinics. Addiction. 2003;98:1513–1520. doi: 10.1046/j.1360-0443.2003.00498.x. [DOI] [PubMed] [Google Scholar]
- 19.Colvin L., Payne J., Parsons D., Kurinczuk J.J., Bower C. Alcohol consumption during pregnancy in nonindigenous west Australian women. Alcohol Clin Exp Res. 2007;31:276–284. doi: 10.1111/j.1530-0277.2006.00303.x. [DOI] [PubMed] [Google Scholar]
- 20.Ethen M., Ramadhani T., Scheuerle A., Canfield M., Wyszynski D., Druschel C. Alcohol consumption by women before and during pregnancy. Matern Child Health J. 2009;13:274–285. doi: 10.1007/s10995-008-0328-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351:1225–1232. [PubMed] [Google Scholar]
- 22.Wurst F.M., Kelso E., Weinmann W., Pragst F., Yegles M., Poromaa I.S. Measurement of direct ethanol metabolites suggests higher rate of alcohol use among pregnant women than found with the AUDIT–a pilot study in a population-based sample of Swedish women. Am J Obstet Gynecol. 2008;198:407.e1–407.e5. doi: 10.1016/j.ajog.2007.10.801. [DOI] [PubMed] [Google Scholar]
- 23.Lawlor D.A., Davey Smith G., Kundu D., Bruckdorfer K.R., Ebrahim S. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet. 2004;363:1724–1727. doi: 10.1016/S0140-6736(04)16260-0. [DOI] [PubMed] [Google Scholar]
- 24.Davey Smith G., Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22. doi: 10.1093/ije/dyg070. [DOI] [PubMed] [Google Scholar]
- 25.Qi L. Mendelian randomization in nutritional epidemiology. Nutr Rev. 2009;67:439–450. doi: 10.1111/j.1753-4887.2009.00218.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Macgregor S., Lind P.A., Bucholz K.K., Hansell N.K., Madden P.A.F., Richter M.M. Associations of ADH and ALDH2 gene variation with self report alcohol reactions, consumption and dependence: an integrated analysis. Hum Mol Genet. 2009;18:580–593. doi: 10.1093/hmg/ddn372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Hashibe M., McKay J.D., Curado M.P., Oliveira J.C., Koifman S., Koifman R. Multiple ADH genes are associated with upper aerodigestive cancers. Nat Genet. 2008;40:707–709. doi: 10.1038/ng.151. [DOI] [PubMed] [Google Scholar]
- 28.Zuccolo L., Fitz-Simon N., Gray R., Ring S.M., Sayal K., Smith G.D. A non-synonymous variant in ADH1B is strongly associated with prenatal alcohol use in a European sample of pregnant women. Hum Mol Genet. 2009;18:4457–4466. doi: 10.1093/hmg/ddp388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Lewis S.J., Zuccolo L., Davey Smith G., Macleod J., Rodriguez S., Draper E.S. Fetal alcohol exposure and IQ at age 8: evidence from a population-based birth-cohort study. PLoS One. 2012;7:e49407. doi: 10.1371/journal.pone.0049407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Boyd A., Golding J., Macleod J., Lawlor D.A., Fraser A., Henderson J. Cohort Profile: the ‘Children of the 90s’ - the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2013;42:111–127. doi: 10.1093/ije/dys064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Fraser A., Macdonald-Wallis C., Tilling K., Boyd A., Golding J., Davey Smith G. Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol. 2013;42:97–110. doi: 10.1093/ije/dys066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Roberts G., Peckitt C., Northstone K., Strachan D., Lack G., Henderson J. Relationship between aeroallergen and food allergen sensitization in childhood. Clin Exp Allergy. 2005;35:933–940. doi: 10.1111/j.1365-2222.2005.02280.x. [DOI] [PubMed] [Google Scholar]
- 33.Davey Smith G. Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health. Genes Nutr. 2011;6:27–43. doi: 10.1007/s12263-010-0181-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Davey Smith G. Assessing intrauterine influences on offspring health outcomes: can epidemiological studies yield robust findings? Basic Clin Pharmacol Toxicol. 2008;102:245–256. doi: 10.1111/j.1742-7843.2007.00191.x. [DOI] [PubMed] [Google Scholar]
- 35.Davey Smith G. Mendelian randomization for strengthening causal inference in observational studies: application to gene by environment interaction. Perspect Psychol Sci. 2010;5:527–545. doi: 10.1177/1745691610383505. [DOI] [PubMed] [Google Scholar]
- 36.Brennan P., Lewis S., Hashibe M., Bell D.A., Boffetta P., Bouchardy C. Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: a HuGE review. Am J Epidemiol. 2004;159:1–16. doi: 10.1093/aje/kwh003. [DOI] [PubMed] [Google Scholar]
- 37.Birley A.J., James M.R., Dickson P.A., Montgomery G.W., Heath A.C., Martin N.G. ADH single nucleotide polymorphism associations with alcohol metabolism in vivo. Hum Mol Genet. 2009;18:1533–1542. doi: 10.1093/hmg/ddp060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Safe, Sensible, Social. The next steps for the Government’s national alcohol strategy 2007. Home Office and Department of Health. Available from: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publichealth/Healthimprovement/Alcoholmisuse/DH_085386. Accessed May 20, 2013.
- 39.Mukherjee R.A., Hollins S., Abou-Saleh M.T., Turk J. Low level alcohol consumption and the fetus. BMJ. 2005;330:375–376. doi: 10.1136/bmj.330.7488.375. [DOI] [PMC free article] [PubMed] [Google Scholar]